FHTX Foghorn Therapeutics Inc.

Nasdaq foghorntx.com


$ 3.80 $ 0.00 (0 %)    

Wednesday, 05-Nov-2025 09:57:25 EST
QQQ $ 621.41 $ 2.97 (0.48 %)
DIA $ 471.75 $ 0.88 (0.19 %)
SPY $ 676.87 $ 1.82 (0.27 %)
TLT $ 89.13 $ -0.38 (-0.42 %)
GLD $ 365.04 $ -1.52 (-0.41 %)
$ 3.53
$ 3.54
$ 3.74 x 70
$ 3.84 x 14
-- - --
$ 2.94 - $ 9.70
490,529
na
199.55M
$ 1.61
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-06-2025 01-01-1970 10-K
5 11-04-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-06-2024 03-31-2024 10-Q
8 03-07-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-04-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 03-09-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 03-10-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-10-2021 06-30-2021 10-Q
19 05-11-2021 03-31-2021 10-Q
20 03-18-2021 12-31-2020 10-K
21 12-04-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 foghorn-therapeutics-q3-eps-025-beats-030-estimate-sales-8153m-beat-6197m-estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of ...

 foghorn-therapeutics-to-present-updates-for-selective-arid1b-selective-cbp-and-selective-ep300-degrader-programs-during-foghorn-hosted-virtual-investor-event

- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and...

 foghorn-therapeutics-q2-eps-028-beats-033-estimate-sales-7557m-beat-6498m-estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of ...

 jmp-securities-reiterates-market-outperform-on-foghorn-therapeutics-maintains-9-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform and maintains ...

 foghorn-therapeutics-q1-eps-030-beats-031-estimate-sales-595m-beat-582m-estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of ...

 jmp-securities-reiterates-market-outperform-on-foghorn-therapeutics-maintains-9-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform and maintains ...

 hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-13-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 ...

 foghorn-therapeutics-presents-new-data-on-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-and-selective-ep300-degrader-programs

FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as th...

 jmp-securities-initiates-coverage-on-foghorn-therapeutics-with-market-outperform-rating-announces-price-target-of-9

JMP Securities analyst Silvan Tuerkcan initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform rat...

 foghorn-therapeutics-will-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-and-ep300-degrader-programs-at-2025-aacr-meeting-in-chicago-april-24-20-2025

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology c...

 hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-13-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 price...

 foghorn-therapeutics-fy-2024-gaap-eps-158-beats-161-estimate-sales-22602m-miss-30713m-estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(1.58) per share which beat the analyst consensus estimate of ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION